A Phase 1 interventional study of Tirzepatide in Renal Insufficiency and End Stage Renal Disease, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 331st largest by enrollment of the 638 interventional ones that give a count, is one of 40 that started in 2018, is one of 89 in phase 1, and was the 506th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 40 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 611 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 8 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
This study's enrollment of 45 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Participants:
Healthy Participants:
-- Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal renal function, assessed by estimated (eGFR) ≥90 milliliters per minute (mL/min) at screening
Participants with Renal Impairment or ESRD:
-- Males or females with stable mild to severe renal impairment, assessed by eGFR or with ESRD (having received hemodialysis for at least 3 months)
Participants with Type 2 Diabetes Mellitus (T2DM) and Renal Impairment or ESRD:
Exclusion Criteria:
All Participants:
Participants with Renal Impairment or ESRD:
Participants with T2DM and Renal Impairment or ESRD:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1 - Tirzepatide 5 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.
Drug: Tirzepatide
Group 2 - Tirzepatide 5mg administered SC to participants with mild renal impairment.
Drug: Tirzepatide
Group 3 - Tirzepatide 5mg administered SC to participants with moderate renal impairment.
Drug: Tirzepatide
Group 4 - Tirzepatide 5mg administered SC to participants with severe renal impairment.
Drug: Tirzepatide
Group 5 - Tirzepatide 5mg administered SC to participants with ESRD.
Drug: Tirzepatide
Administered SC.
Also known as: LY3298176
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) of Tirzepatide was evaluated.
Time frame: Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose
PK: Maximum Concentration of Tirzepatide
Cmax is the maximum observed concentration of Tirzepatide.
Time frame: Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose
PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf])
Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of Tirzepatide was evaluated.
Time frame: Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose
| Milestone | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) |
|---|---|---|---|---|---|
| Started | 14 | 8 | 8 | 7 | 8 |
| Received at least one dose of study drug | 14 | 8 | 8 | 7 | 8 |
| Completed | 13 | 8 | 8 | 7 | 8 |
| Not completed | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) of Tirzepatide was evaluated.
| Nanogram*hour per Millilitre (ng*h/mL) | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast]) | 78400 ± 24 | 81900 ± 36 | 98300 ± 32 | 81200 ± 9 | 88500 ± 14 |
Cmax is the maximum observed concentration of Tirzepatide.
| Nanogram per Millilitre (ng/mL) | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) |
|---|---|---|---|---|---|
| PK: Maximum Concentration of Tirzepatide | 339 ± 21 | 353 ± 42 | 369 ± 36 | 417 ± 11 | 347 ± 30 |
Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of Tirzepatide was evaluated.
| Nanogram*hour per Millilitre (ng*h/mL) | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) |
|---|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf]) | 80500 ± 25 | 84200 ± 37 | 10400 ± 32 | 83000 ± 10 | 93400 ± 12 |
Collected over Up to 28days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirzepatide - Control | 0/14 (0%) | 0/14 (0%) | 1/14 (7.1%) |
| Tirzepatide - Mild Renal Impairment | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Tirzepatide - Moderate Renal Impairment | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Tirzepatide - Severe Renal Impairment | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Tirzepatide - End Stage Renal Disease (ESRD) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/14 | 2/8 | 0/8 | 0/7 | 0/8 |
| VomitingGastrointestinal disorders | 0/14 | 0/8 | 0/8 | 1/7 | 2/8 |
| AnaemiaBlood and lymphatic system disorders | 0/14 | 0/8 | 0/8 | 1/7 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/14 | 1/8 | 1/8 | 1/7 | 0/8 |
| HeadacheNervous system disorders | 1/14 | 0/8 | 0/8 | 1/7 | 0/8 |
| Orthostatic hypotensionVascular disorders | 0/14 | 0/8 | 0/8 | 1/7 | 0/8 |
| Abdominal distensionGastrointestinal disorders | 0/14 | 0/8 | 1/8 | 0/7 | 0/8 |
| NauseaGastrointestinal disorders | 0/14 | 1/8 | 0/8 | 0/7 | 1/8 |
| ContusionInjury, poisoning and procedural complications | 0/14 | 0/8 | 1/8 | 0/7 | 0/8 |
| Back painMusculoskeletal and connective tissue disorders | 0/14 | 1/8 | 1/8 | 0/7 | 0/8 |
All randomized participants.
| Age, Continuous(years) | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) | Total |
|---|---|---|---|---|---|---|
| Mean | 58.1 ± 7.6 | 63.3 ± 6.6 | 68.8 ± 14.1 | 60.3 ± 9.3 | 52.9 ± 7.2 | 60.3 ± 10.1 |
| Sex: Female, Male(Participants) | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 3 | 4 | 1 | 2 | 15 |
| Male | 9 | 5 | 4 | 6 | 6 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 3 | 4 | 0 | 14 |
| Not Hispanic or Latino | 12 | 3 | 5 | 3 | 8 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 2 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 2 | 3 | 1 | 8 | 21 |
| White | 7 | 6 | 3 | 6 | 0 | 22 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Tirzepatide - Control | Tirzepatide - Mild Renal Impairment | Tirzepatide - Moderate Renal Impairment | Tirzepatide - Severe Renal Impairment | Tirzepatide - End Stage Renal Disease (ESRD) | Total |
|---|---|---|---|---|---|---|
| United States | 14 | 8 | 8 | 7 | 8 | 45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Aug 2019, 16 months.
Results were first posted in Mar 2023, 3 years 7 months after primary completion.
Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 16 months is above that.
Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide